Program
Flonoltinib Maleate orally
Its studies are mostly in Primary Myelofibrosis, led by Chengdu Zenitar Biomedical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technology | 11 open or running | phase 2since Aug 2, 2026 | Aug 2, 2026 | Nov 2028phase 2 · NCT07750574 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 2, 2026First study: phase 2 study in Primary MyelofibrosisFirst studyNCT07750574 · 105 planned
Ahead
- Nov 2028Primary completion: phase 2 study in Primary MyelofibrosisNCT07750574
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07750574Primary Myelofibrosis | 2 | Not yet recruiting | Nov 2028 | 105 |
How it is read
Names in the registry
- “Flonoltinib Maleate orally”, 3 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.